Hongo T, Yamada S, Yajima S, Watanabe C, Fujii Y, Kawasaki H, Yazaki M, Hanada R, Horikoshi Y
Department of Pediatrics, Hamamatsu University School of Medicine, Japan.
Int J Hematol. 1999 Dec;70(4):268-77.
The purpose of this study was to investigate the biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia (ALL). We carried out in vitro tests with a 4-day culture and a methyl-thiazol-tetrazolium assay on bone marrow samples from 209 children newly diagnosed with ALL. After testing the resistance of leukemic cells to 14 drugs, we classified the patients into two groups according to their sensitivity to three drugs (prednisolone, L-asparaginase, and vincristine) used in remission induction therapy. The three-drug resistant group (RR: sensitive to no drugs or to one drug) correlated with both short-term and long-term treatment failure. Three-year event-free survival (95% confidence interval) for the sensitive group (SS: sensitive to two or three drugs) was 0.813 (0.773-0.853) and that of the RR group was 0.616 (0.569-0.669) (P = 0.0001). Univariate analysis showed that Philadelphia-chromosome (Ph1) positivity and immunophenotype of mixed lineage were also prognostic factors in the 209 patients. The prognosis of the SS/RR drug resistance profile within 14 Ph1 patients was marginally significant (P = 0.062). Multivariate Cox regression analysis showed that Ph1 was an overwhelmingly adverse factor in event-free survival, with a relative hazard of 5.37 (2.57-11.21, P < 0.0001), followed by RR, with a relative hazard of 2.98 (1.69-5.25, P = 0.0001). Furthermore, we clarified the characteristics of the RR group by examination of the pattern of drug resistance to other drugs in comparison with the SS group. The leukemic cells of RR patients were more resistant than those of SS patients (P < 0.0001) to all the drugs tested, with resistance ratios of 1.6 to 13.1 (mean 3.4). In conclusion, in vitro three-drug resistance at the initial stage is an important independent predictor of treatment failure for both induction response and long-term outcome in childhood ALL.
本研究旨在探讨儿童急性淋巴细胞白血病(ALL)体外对泼尼松龙、L-天冬酰胺酶和长春新碱的三联耐药的生物学特性及预后价值。我们对209例新诊断ALL患儿的骨髓样本进行了为期4天的体外培养及甲基噻唑基四氮唑蓝检测。在检测白血病细胞对14种药物的耐药性后,我们根据患儿对缓解诱导治疗中使用的三种药物(泼尼松龙、L-天冬酰胺酶和长春新碱)的敏感性将患者分为两组。三联耐药组(RR:对无药物或仅一种药物敏感)与短期和长期治疗失败均相关。敏感组(SS:对两种或三种药物敏感)的三年无事件生存率(95%置信区间)为0.813(0.773 - 0.853),RR组为0.616(0.569 - 0.669)(P = 0.0001)。单因素分析显示,费城染色体(Ph1)阳性和混合谱系免疫表型也是这209例患者的预后因素。14例Ph1患者中SS/RR耐药谱的预后差异边缘显著(P = 0.062)。多因素Cox回归分析显示,Ph1是无事件生存的压倒性不利因素,相对风险为5.37(2.57 - 11.21,P < 0.0001),其次是RR,相对风险为2.98(1.69 - 5.25,P = 0.0001)。此外,通过与SS组比较检测对其他药物的耐药模式,我们明确了RR组的特征。RR患者的白血病细胞对所有检测药物的耐药性均高于SS患者(P < 0.0001),耐药比为1.6至13.1(平均3.4)。总之,初始阶段的体外三联耐药是儿童ALL诱导反应和长期预后治疗失败的重要独立预测因素。